touchONCOLOGY joins Prof Rahul Aggarwal (UCSF School of Medicine, San Francisco, CA, USA), to discuss the interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumour malignancies.
Questions
1. Could you tell us a little about ARID1A alterations in solid tumours and potential therapeutic targets in ARID1A-mutated tumours? (00:15-01:12)
2. What is the rationale for the use of ceralasertib in patients harbouring ARID1A-deficient solid tumours? (01:12-02:10)
3. What were the aims and design of the study you are presenting? (02:10-03:20)
4. How well were the clinical endpoints achieved? (03:20-04:10)
5. What will stage 2 of the study entail and which patients will be eligible? (04:10-04:45)
Disclosures: UCSF School of Medicine has received research funding from AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
